There have been impressive clinical responses in select tumors to targeted therapy, but for most cancers the gains are short-lived, and the cancer progresses. It has been found that a protein called Hsp90 chaperone is over abundant in cancer cells. The Hsp90 chaperones are responsible for stabilizing proteins and maintaining multiple mechanisms of tumor growth. This first-in-human study will assess the safety of gamitrinib, a new agent that directly targets Hsp90 in patients with advanced cancer. Patients with metastatic castrate resistant prostate cancer and glioblastoma will be encouraged to participate given the preclinical evidence of gamitrinib activity in these cancers.
Trial Registration: ClinicalTrials.gov Identifier: NCT04827810